| Literature DB >> 33889551 |
Mohammed Aldhaeefi1, Zabreen Tahir2, David J Cote3, Saef Izzy2,4,3, Joseph El Khoury2,4,5.
Abstract
Objectives: The impact of demographics and comorbidities on the duration of COVID-19 nasopharyngeal swab PCR positivity remains unclear. The objective of our analysis is to determine the impact of age, intensive care unit (ICU) admission, comorbidities, and ethnicity on the duration of COVID-19 PCR positivity among hospitalized patients in a large group of hospital. Method: We studied 530 patients from a large hospital system and time to SARS-CoV-2 virus RNA PCR negativity at any-time during hospitalization or following discharge from the hospital was the primary endpoint. We included patients 18 years or older who tested positive for COVID-19 during an inpatient, outpatient, or emergency room visit between February 1, 2020, and April 14, 2020.Entities:
Keywords: COVID19; PCR; age; comorbidities; positivity
Year: 2021 PMID: 33889551 PMCID: PMC8056299 DOI: 10.3389/fcimb.2021.650753
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Patients Comorbidities.
| Comorbidity* | Number of Patients (n=530) |
|---|---|
| Hypertension | 273 (51.5) |
| Hyperlipemia | 204 (38.5) |
| Diabetes | 195 (36.8) |
| Obesity | 107 (20.2) |
| Obstructive lung disease | 79 (14.9) |
| Coronary artery disease | 56 (10.6) |
| Chronic kidney disease | 56 (10.6) |
| Obstructive sleep apnea | 34 (6.4) |
| Congestive heart failure | 31 (5.8) |
| Autoimmune disease | 25 (4.7) |
| Cerebrovascular disease | 24 (4.5) |
| Transplant | 15 (2.8) |
| Interstitial lung disease | 1 (0.2) |
*n (%).
Figure 1Percent of patients remaining positive up to 8 weeks after the first positive PCR test.
Predictors of negative test after 4 weeks compared to those within 4 weeks.
| Univariable | p-value | |
|---|---|---|
| OR (95% CI) | ||
|
| ||
| Female | Reference | |
| Male | 1.2 (0.9-1.8) | 0.21 |
|
| ||
| 18-40 | Reference | |
| 41-70 | 1.4 (0.8-2.2) | 0.23 |
| >70 | 1.9 (1.1-3.3) |
|
|
| ||
| White | Reference | |
| Hispanic | 0.97 ().7-1.5) | 0.94 |
| Black | 0.62 (0.4-1.0) | 0.07 |
| Other | 0.54 (0.2-1.3) | 0.15 |
| Unknown | 0.52 (0.3-1.1) | 0.07 |
|
| ||
| Former | 1.7 (0.7-3.9) | 0.22 |
| Current | Reference | |
| Never | 1.5 (0.7-3.4) | 0.33 |
|
| ||
| No | Reference | |
| Yes | 1.24 (0.9-1.8) | 0.23 |
|
| ||
| Hypertension | 1.4 (1.0-2.1) |
|
| Hyperlipidemia | 1.5 (1.0-2.1) |
|
| Diabetes mellitus | 1.4 (0.9-2.0) | 0.09 |
| Obesity | 1.6 (1.0-2.5) |
|
| Obstructive lung disease | 1.3 (0.8-2.2) | 0.29 |
| Coronary Artery disease | 2.2 (1.2-4.3) |
|
| Cerebrovascular disease | 0.9 (0.4-2.3) | 0.91 |
| Chronic kidney disease | 2.7 (1.4-5.4) |
|
| Congestive heart failure | 1.3 (0.6-2.8) | 0.55 |
| Obstructive sleep apnea | 1.5 (0.7-3.2) | 0.32 |
| Auto-immune disease | 2.7 (1.1-8.2) | 0.05 |
| Cancer | 1.3 (0.7-2.5) | 0.51 |
| Transplant | 0.8 (0.3-2.2) | 0.63 |
Bolded values are statistically significant.
Figure 2Dot-plot of mean SARS-CoV-2 Ct values for the first and last positive PCR tests.